-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 1/24
NCBIBookshelf.AserviceoftheNationalLibraryofMedicine,NationalInstitutesofHealth.
DeGrootLJ,BeckPeccozP,ChrousosG,etal.,editors.Endotext[Internet].SouthDartmouth(MA):MDText.com,Inc.2000.
InsulinPharmacology,TypesofRegimens,andAdjustmentsLisaKroon,PharmD,CDEProfessorandExecutiveViceChair,DepartmentofClinicalPharmacy,SchoolofPharmacy,UniversityofCaliforniaSanFrancisco,SanFrancisco,[email protected]
IraD.Goldfine,M.D.ProfessorofMedicine,DepartmentofMedicine,DiabetesandEndocrineResearch,UniversityofCaliforniaSanFrancisco/Mt.ZionMedicalCenter,SanFrancisco,[email protected]
SinanTanyolac,M.D.VisitingScientist,DepartmentofMedicine,UniversityofCaliforniaSanFrancisco,SanFrancisco,[email protected]
LastUpdate:October1,2010.
INTRODUCTION
Withtheintroductionofseveralnewinsulinssince1996,insulintherapyoptionsfortype1andtype2diabeticshaveexpanded.Insulintherapiesarenowabletomorecloselymimicphysiologicinsulinsecretionandthusachievebetterglycemiccontrolinpatientswithdiabetes.Thischapterreviewsthepharmacologyofinsulins(usingacomparativeapproach),typesofinsulinregimensandtherapeuticadjustmentofthem,andprovidesanoverviewofinsulinpumptherapy.
PHARMACOLOGY
In1922,Canadianresearcherswerethefirsttodemonstrateaphysiologicresponsetoinjectedanimalinsulininapatientwithtype1diabetes.In1955,insulinwasthefirstproteintobefullysequenced.Theinsulinmoleculeconsistsof51aminoacidsarrangedintwochains,anAchain(21aminoacids)andBchain(30aminoacids)thatarelinkedbytwodisulfidebonds (Figure1).ProinsulinistheinsulinprecursorthatistransportedtotheGolgiapparatusofthebetacellwhereitisprocessedandpackagedintogranules.Proinsulin,asinglechain86aminoacidpeptide,iscleavedintoinsulinandCpeptide(aconnectingpeptide)botharesecretedinequimolarportionsfromthebetacelluponstimulationfromglucoseandotherinsulinsecretagogues.WhileCpeptidehasnoknownphysiologicfunction,itcanbemeasuredandifpresent,indicatesapersonhasfunctioningbetacells.
Figure1 InsulinStructure
Insulinexertsitseffectonglucosemetabolismbybindingtoinsulinreceptorsthroughoutthebody.Uponbinding,insulinpromotesthecellularuptakeofglucoseintofatandskeletalmuscleandinhibitshepaticglucoseoutput,thusloweringthebloodglucose.(seeInsulinsignalingandaction:glucose,lipids,protein)
Commerciallyavailableinsulinsareusedforallpatientswithtype1diabetesinwhominsulinisrequiredforsurvival,andforpatientswithtype2diabeteswhendiet/exercise,oralagentsandotherinjectablehypoglycemicagents(i.e.,incretinemimeticagents/GLP1analogs)nolongerprovideadequateglucosecontrol.
SourcesofInsulin
WiththeavailabilityofhumaninsulinbyrecombinantDNAtechnologyinthe1980s,useofanimalinsulindeclined
[1]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 2/24
dramatically.Beefinsulin,beefporkandporkinsulinarenolongercommerciallyavailable.TheFDAmayallowforpersonalimportationofbeefinsulinfromaforeigncountryifapatientcannotbetreatedwithhumaninsulin .Beefinsulindiffersfromhumaninsulinby3aminoacidsandporkinsulindiffersbyoneaminoacid .
Currently,intheUSA,mostinsulinsusedareeitherhumaninsulinand/oranalogsofhumaninsulin.TherecombinantDNAtechniqueforhumaninsulininvolvesinsertionofthehumanproinsulingeneintoeitherSaccharomycescerevisiae(bakersyeast)oranonpathogeniclaboratorystrainofEscherichiacoli(Ecoli)whichserveastheproductionorganism.Humaninsulinisthenisolatedandpurified .
InsulinAnalogs
RecombinantDNAtechnologyhasallowedforthedevelopmentandproductionofanalogstohumaninsulin.Withanalogs,theinsulinmoleculestructureismodifiedslightlytoalterthepharmacokineticspropertiesoftheinsulin,primarilyaffectingtheabsorptionofthedrugfromthesubcutaneoustissue.TheB26B30regionoftheinsulinmoleculeisnotcriticalforinsulinreceptorrecognitionanditisinthisregionthataminoacidsaregenerallysubstituted .Thus,theinsulinanalogsarestillrecognizedbyandbindtotheinsulinreceptor.ThestructuresofthreeinsulinanalogsareshowninFigure2(insulinaspart,lisproandglulisine)andFigure3(insulinglargineanddetemir).
Figure2 InsulinAspart,GlulisineandLisproStructures
[2]
[3]
[4] [5] [6] [7] [8] [9] [10] [11]
[12]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 3/24
Figure3 InsulinGlargineandDetemirStructures
Becauseinsulinanalogsaremodifiedhumaninsulin,thesafetyandefficacyprofilesoftheseinsulinshavebeencomparedtohumaninsulin .InsulinandIGF1receptorbindingaffinities(IGFinsulinlikegrowthfactor),metabolicandmitogenicpotenciesofinsulinlispro,insulinaspart,insulinglargineandinsulindetemirrelativetohumaninsulinhasbeenassessed.Insulinlisproandaspartaresimilartohumaninsulinonalloftheaboveparameters,exceptinsulinlisprowasfoundtobe1.5foldmorepotentinbindingtotheIGF1receptorcomparedtohumaninsulin.Insulinglarginewasfoundtohavea6to8foldincreaseinmitogenicpotencyandIGF1receptoraffinitycomparedtohumaninsulin.Insulindetemirwasfoundtotobemorethan5foldlesspotentthanhumaninsulininbiningtoIGF1.Whiletheclinicalsignificanceofthesedifferencesisnotknown,theylikelydonotrepresentanysignificantconcern .
Immunogenicity
Becauseporkandbeefinsulindifferfromhumaninsulinby1and3aminoacidsrespectively,theyaremoreimmunogenicthanexogenoushumaninsulin.Olderformulationsofinsulinwerelesspure,containingisletcellpeptides,proinsulin,Cpeptide,pancreaticpolypeptides,glucagons,andsomastostatin,whichcontributedtoimmunogenicityofinsulin .Componentsofinsulinpreparations(e.g.,zinc,protamine)andsubcutaneousinsulinaggregatesarealsothoughttocontributetoantibodyformation .Commerciallyavailablehumaninsulinsarenowvirtuallyfreeofcontaminantsandcontain
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 4/24
Patientswhoexperienceatrueallergicreactiontoinsulinoftenhavereceivedinsulininthepast,andexperiencetheallergicreactionafterinsulinisrestarted.AnotherallergicreactionseenwithanimalinsulinswasadelayedlocalreactionthatwasIgGmediated .InsulintherapycanalsoresultintheproductionofinsulinantibodiesoftheIgGclass,whichneutralizeinsulin.AnimmunologicalinsulinresistancecanoccurinpatientswithveryhightitersofIgGantibodies.
Lipodystrophyseenwithinsulinreferstotwoconditions:lipoatrophyandlipohypertrophy.Lipoatrophyisanimmunemediatedconditioninwhichthereislossoffatattheinsulininjectionsites .Lipoatrophyoccursmuchlessfrequentlywithpurifiedhumaninsulins.Treatmentforpatientswhowereonananimalinsulinwasinjectionwithhumaninsulinattheatrophiedsite.Lipohypertrophyisanonimmunologicalsideeffectofinsulinresultingfromrepeatedadministrationofinsulinatthesameinjectionsite.
Concentration
IntheUnitedStates,allinsulinsareavailableintheconcentrationof100units/ml(denotedasU100).Insulinsyringesaredesignedtoaccommodatethisconcentrationofinsulin.Regularhumaninsulin(HumulinR,Lilly)isavailableinamoreconcentratedinsulin,U500(500units/ml),howeverthispreparationisusedprimarilyinaspecializedinstitutionalsettingorforrarecasesofextremeinsulinresistance,whereverylargedosesofinsulin(generally>200unitsperday)arerequired.SpecificsyringesforU500insulinarenotavailableandextremecautionmustbetakenaseachmarkedunitonaU100syringewillactuallydeliver5unitsofinsulin.
OutsidetheUnitedStates,alessconcentratedinsulinpreparation,U40,(40units/ml)isstillavailableandsometimesused.SpecificU40syringesareusedwiththisinsulin.Itisimportantthatpatientstravelingfromonecountrytothenext,beawareoftheconcentrationofinsulintheyuse,andthattheappropriatesyringeisused.
PhysicalandChemicalProperties
Regularhumaninsuliniscrystallinezincinsulindissolvedinaclearsolution.Itmaybeadministeredbyanyparenteralroute:subcutaneous,intramuscular,orintravenous.Insulinaspart,glulisineandlisproarealsosolublecrystallinezincinsulin,butareintendedforsubcutaneous(subQ)injection.NPH,orneutralprotamineHagedorn,isasuspensionofregularinsulincomplexedwithprotaminethatdelaysitsabsorption.Insulinsuspensionsshouldnotbeadministeredintravenously.Allinsulins,exceptinsulinglargine,areformulatedtoaneutralpH.
LongactingInsulinglargineisasoluble,clearinsulin,andhasapHof4.0.ItsacidicpHiscriticalforitssubQabsorptioncharacteristicsandwillbediscussedfurtherunderpharmacokinetics.Insulinglargineshouldnotbemixedwithotherinsulins,andshouldonlybeadministeredsubcutaneously .
InsulindetemirisalongactinginsulinanalogthathasafattyacidcoupledtoitsothatitbindstoalbumininthesubQtissueresultingindelayedabsorption,proloningitsdurationofaction.Likeinsulinglargine,insulindetemirshouldnotbemixedwithotherinsulins,andshouldbeinjectedsubcutaneously.
Pharmacokinetics
Absorption
InsulinadministeredviaSCinjectionisabsorbeddirectlyintothebloodstream,withthelymphaticsystemplayingaminorroleintransport .TheabsorptionofhumaninsulinaftersubQabsorptionistheratelimitingstepofinsulinactivity.ThisabsorptionisinconsistentwiththecoefficientsofvariationofT50%(timefor50%oftheinsulindosetobeabsorbed)varying~25%withinanindividualandupto50%betweenpatients .Mostofthisvariabilityofinsulinabsorptioniscorrelatedtobloodflowdifferencesatthevarioussitesofinjection(abdomen,deltoid,gluteus,andthigh) .Forregularinsulin,theimpactofthisisa~2timesfasterrateofabsorptionfromtheabdomenthanothersubcutaneoussites .Theclinicalsignificanceofthisisthatpatientsshouldavoidrandomuseofdifferentbody
[20]
[21]
[22]
[23]
[24] [25]
[26]
[27]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 5/24
regionsfortheirinjections.Forexample,ifapatientpreferstousetheirthighforanoontimeinjection,thissiteshouldbeusedconsistentlyforthisinjection.Forsimplicity,however,theabdomenisoftenrecommendedasthepreferredsiteofinjectionbecauseitistheleastsusceptibletofactorsaffectinginsulinabsorption(seeTable1).Insulinaspart,glulisineandlisproappeartohavelessdaytodayvariationinabsorptionratesandalsolessabsorptionvariationfromthedifferentbodyregions .Insulinglarginespharmacokineticprofileissimilarafterabdominal,deltoidorthighSCadministration .
AgeneralprincipleforfactorsthatcanalterinsulinabsorptionisthatwhenlocalbloodflowinthesubQtissueischanged,theabsorptionrateofinsulinwillalsobeaffected.AfactorthatincreasessubQbloodflowwillincreasetheabsorptionrateandviceversa.SeeTable1forfactorsthataffectinsulinabsorption.
Table1 FactorsAffectingInsulinAbsorption( )
Factor Comment
Exerciseofinjectedarea Strenuousexerciseofalimbwithin1hourofinjection.Clinicallysignificantforregularhumaninsulin.
Localmassage WhileitisOKtopressontheinjectionsitetopreventseepage,thesiteshouldnotberubbedvigorouslyormassaged.
Temperature Heatcanincreaseabsorptionrate.Avoidthesauna,shower,hotbathsoonafterinjection.Coldhastheoppositeeffect.
Siteofinjection Insulinisabsorbedfasterfromtheabdomen.Lessclinicallyrelevantwithrapidactinginsulins,insulinglargineandinsulindetemir.
Lipohypertrophy Injectionintohypertrophiedareasdelaysinsulinabsorption.
Jetinjectors Increaseabsorptionrate.
Insulinmixtures Absorptionratesareunpredictablewhensuspensioninsulinsarenotmixedadequately(i.e.,theyneedtoberesuspended).
Insulindose Largerdoseshavedelayinactionandincreasedduration.
Physicalstatus(solublevs.suspension)
Suspensioninsulinsmustbesufficientlyresuspendedpriortoinjectiontoreducevariability.
Distribution
CirculatinginsulinisdistributedinequilibriumbetweenfreeinsulinandinsulinboundtoIgGantibodies .Thepresenceofinsulinantibodiescandelaytheonsetofinsulinactivity,reducethepeakconcentrationoffreeinsulin,andprolongthebiologichalflifeofinsulin .
Elimination
Thekidneysandliveraccountforthemajorityofinsulindegradation.Normally,theliverdegrades~60%ofinsulinreleasedbythepancreas(insulindeliveredthroughportalveinbloodflow)andthekidneys~3545% .Wheninsulinisinjectedexogenously,thedegradationprofileisalteredsinceinsulinisnolongerdelivereddirectlytotheportalvein.ThekidneyhasagreaterroleininsulindegradationwithsubQinsulin(~60%),withtheliverdegrading~3040%
.
Becausethekidneysareinvolvedinthedegradationofinsulin,renaldysfunctionwillreducetheclearanceofinsulinandprolongitseffect.Thisdecreasedclearanceisseenwithbothendogenousinsulinproduction(eithernormalproductionorthatstimulatedbyoralagents)andexogenousinsulinadministration.Renalfunctiongenerallyneedstobegreatlydiminishedbeforethisbecomesclinicallysignificant .
[28] [29] [30] [31]
[32]
[33] [34] [35]
[36]
[37]
[38]
[
39]
[40]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 6/24
Pharmacodynamics
Theonset,peak,anddurationofeffectarethemostclinicallysignificantdifferencesamongtheinsulins.Insulinpharmacodynamicsreferstothemetaboliceffectofinsulin.Commerciallyavailableinsulinscanbecategorizedasrapidacting,shortacting,intermediateacting,andlongacting.ThecurrentinsulinsavailableintheUnitedStatesarelistedinTable2.Insulinpharmacodynamics(i.e.,onset,peakandduration)ofthevariousinsulins)areshowninTable3.Itisimportanttonotethatrangesarelistedfortheonset,peakandduration,accountingforintra/interpatientvariability.Eachpatientwillhaveanindividualpatternofresponse.Byhavingthepatientselfmonitortheirbloodglucosefrequently,thepatientspecifictimeactionprofileofthespecificinsulincanbebetterappreciated.Figures4a4c
graphicallyshowthetimeactivityprofilesforthevariousinsulins.
Table2I nsulinsCommerciallyAvailableintheUS
Category/NameofInsulin
Source BrandName(manufacturer) Preparation(s)
RapidActingInsulinLisproInsulinAspartInsulinGlulisine
RecombinantDNARecombinantDNARecombinantDNA
Humalog(Lilly)Novolog(NovoNordisk)Apidra(sanofiaventis)
vial,cartridge,disposablepenvial,cartridge,disposablepenvial,disposablepen
ShortActingRegularHuman
RecombinantDNA HumulinR(Lilly)NovolinR(NovoNordisk)
vialvial
IntermediateActingNPHHuman
RecombinantDNA HumulinN(Lilly)NovolinN(NovoNordisk)
vial,disposablepenvial
LongActingInsulinDetemirInsulinGlargine
RecombinantDNARecombinantDNA
Levemir(NovoNordisk)Lantus(sanofiaventis)
vial,disposablepenvial,cartridge,disposablepen
InsulinMixturesNPH/Regular(70%/30%)HumanLisproProtamine/Lispro(50%/50%)LisproProtamine/Lispro(75%/25%)AspartProtamine/Aspart(70%/30%)
RecombinantDNARecombinantDNARecombinantDNARecombinantDNA
Humulin70/30(Lilly)Novolin70/30(NovoNordisk)HumalogMix50/50(Lilly)HumalogMix75/25(Lilly)NovologMix70/30(NovoNordisk
vial,disposablepenvialvial,disposablepenvial,disposablepenvial,disposablepen
Note:Allinsulinanalogsareavailablebyprescriptiononly.OnAugust17,2009,NovoNordiskannouncedtheNovolinInnoletR,N,and70/30devicesandtheNovolinR,Nand70/30PenFillcartridgeswouldnolongerbeavailableafterDecember31,2009.
Table3I nsulinPharmacodynamics( )
[41] [
42] [43] [44]
[45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 7/24
Insulin Onset(hr) Peak(hr) Duration(hr) Appearance
InsulinLispro within15min 1 35 Clear
InsulinAspart within15min 13 35 Clear
InsulinGlulisine .25.5 .51 4 Clear
Regular 1 24 58 Clear
NPH 12 410 14+ Cloudy
InsulinDetemir 34 68(thoughrelativelyflat) upto2024 Clear
InsulinGlargine 1.5 flat 24 Clear
LisproMix50/50 .25.5 .53 1424 Cloudy
LisproMix75/25 .255 .52.5 1424 Cloudy
AspartMix70/30 .1.2 14 1824 Cloudy
Note:Patientspecificonset,peak,durationmayvaryfromtimeslistedintable,
Peakanddurationareoftenverydosedependentwithshorterdurationofactionswith
smallerdosesandviceversa.
Figure4a PharmacodynamicProfilesofaRapidInsulinAnalog(insulinlispro)andRegularInsulin.
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 8/24
Figure4b PharmacodynamicProfilesofLongActingandIntermediateActing
BasalInsulins.
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 9/24
Figure4c PharmacodynamicProfile:LisproNPLinComparisonwithNPH
DoseDependentEffect
ThepharmacodynamicsofregularandNPHareparticularlyaffectedbythesizeofthedose .Largerdosescancauseadelayinthepeakandincreasethedurationofaction.Forexample,injecting4unitsofNPHwillhaveasignificantlydifferenttimeactionprofilecomparedto30unitsofNPH.
RapidActingInsulins
InsulinLispro(Humalog)
Insulinlispro[Lys(B28),Pro(B29)]isaninsulinanalogthatwasapprovedin1996(Humalog).TheB28(proline),B29(lysine)aminoacidsequenceoftheinsulinmoleculeisreversedtobelysineprolineresultinginarapidabsorption,within15minutes.Becauseitisabsorbedmorerapidly,itsonsetandpeakaresooner(anddurationshorter)comparedtoregularinsulin.Insulinlisproisalsoapprovedforinjectionimmediatelyafterameal.Becauseinsulinlisprocanbeinjectedjustbefore(orafter)themealversuswaiting30minuteswithregularinsulin,patientsmayfinditprovidesthemwithmoreflexibilityandconveniencefortheirmealtimeinsulininjection.Insulinlisprocanbemoreeffectiveinloweringpostprandialbloodglucoselevelsandhasareducedriskofhypoglycemiacomparedtoregularinsulin
.Thereasoninsulinlisproisassociatedwithlesshypoglycemiaisduetobettermatchingofinsulineffectandfoodabsorption .Insulinlisprohasbeenstudiedforuseininsulinpumpsand,FDAapprovedforthisindicationin2004. .Intherarecaseofseverehumaninsulinallergy,insulinlisprohasbeenshowntobelessimmunogenic .
InsulinAspart(Novolog)
[58]
[59] [
60] [61]
[62]
[63] [64] [65]
[66]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 10/24
InsulinaspartisahumaninsulinanalogapprovedJune7,2000(Novolog).TheB28aminoacidprolineissubstitutedwithasparticacidresultinginarapidonsetofactivity.Insulinaspartshouldbeinjected510minutesbeforethemeal.Advantageslistedaboveforinsulinlisproarethesameforinsulinaspart .TheinsulinaspartisFDAapprovedforuseininsulinpumps .
Whileonamolarbasisinsulinaspartandlisprohaveidenticalinvivopotencycomparedtoregularhumaninsulin,higherpeakconcentrationsareachievedwiththerapidactinginsulins .Thus,whilea1:1conversionisoftenusedfortheinitialswitchfromregularinsulintoinsulinaspart,glulisineorlispro,overtime,apatientsrapidactinginsulindosemayneedtobeadjusted,oftenreduced.Thisdosingchangeisalsoduetothebettermatchingofthepeakoftheinsulinwiththemeal,thusachievingbetterpostprandialcontrol.
InsulinGlulisine(Apidra)
InsulinglulisineisarapidactinginsulinanaloguethatdiffersfromhumaninsulininthattheaminoacidasparagineatpositionB3isreplacedbylysineandthelysineinpositionB29isreplacedbyglutamicacid.Chemically,itis3Blysine29Bglutamicacidhumaninsulin.Wheninjectedsubcutaneously,itsonsetofactionismorerapidandachieveshigherconcentrationscomparedtohumaninsulinonaunitperunitbasis.Whenusedasamealtimeinsulin,thedoseshouldbegivenwithin15minutesbeforeamealorwithin20minutesafterstartingameal.Insulinglulisinealsoisbeingusedininsulinpumps .InsulinglulisinehasbeenavailableinUSAsince2007andFDAapprovedin2004.
ShortActingInsulin(Regular)
Regularinsulinhasanonsetofactionof3060minutes.Itshouldbeinjectedapproximately30minutesbeforethemeal.Adherencetothisschedulecanbeinconvenientanddifficultforsomepatients.
IntermediateActingInsulins(NPH)
NPH,whichstandsforNeutralProtamineHagedorn,wascreatedin1936byHansChristianHagedornandB.NormanJensen.Thesescientistsdiscoveredthattheeffectsofsubcutaneouslyinjectedinsulincouldbeprolongedbytheadditionofprotamine,aproteinthattheyobtainedfromthe"milt"orsemenofrivertrout.NPHinsuliniscategorizedasanintermediateactinginsulin,whoseonsetofactionisapproximately2hours,peakeffectat614hours,anddurationofactionupto24hours(dependingonthesizeofthedose).Intermediateactinginsulinscanserveabasalinsulinand/orprandialinsulindependingontimeofadministration.NPHinsulinisavailableinvariouscombinationswitheitherregularinsulinorshortactinginsulins(Table2).
LongActingInsulins
Longactinginsulinsservetoprovideabasal(orbaseline)levelofinsulin.
InsulinGlargine(Lantus)
Insulinglargine(21AGly30BaLArg30BbLArghumaninsulin)isaninsulinanalogapprovedApril20,2000(Lantus).Itconsistsoftwomodificationstohumaninsulin.TwoargininesareaddedtotheCterminusoftheBchainshiftingtheisoelectricpointoftheinsulinfromapHor5.4to6.7 .ThischangemakestheinsulinmoresolubleatanacidicpHandinsulinglargineisformulatedatapHof4.0 .ThesecondmodificationisattheA21position,whereasparagineisreplacedbyglycine.Thissubstitutionpreventsdeamidationanddimerisationthatwouldoccurwithacidsensitiveasparagine.Wheninsulinglargineisinjectedintosubcutaneoustissue,whichisatphysiologicpH,theacidicsolutionisneutralized.Microprecipitatesofinsulinglargineareformed,fromwhichsmallamountsofinsulinarereleasedthroughouta24hourperiod,resultinginalowlevelofinsulinthroughouttheday .Thebiologicalactivityofinsulinglargineisduetoitsabsorptionkineticsandnotadifferentpharmacodynamicactivity(e.g.,stimulationofperipheralglucoseuptake) .
Itiscriticalthatinsulinglarginenotbemixedinthesamesyringewithanyanotherinsulinorsolutionbecausethiswill
[67]
[68] [69]
[70]
[71]
[72]
[73]
[74]
[75]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 11/24
alteritspHandthusaffectitsabsorptionprofile.Lantusmaybegivenatanytimeofday.InsulinglarginehasbeenshowntohavelessnocturnalhypoglycemiawhenusedatbedtimecomparedwithNPHinsulin .
InsulinDetemir(Levemir)
InsulindetemirisalongactinghumaninsulinanalogformaintainingthebasallevelofinsulinitstradenameisLevemir.ItisaninsulinanaloginwhichtheB30aminoacidisomittedandaC14fattyacidchain(myristicacid)isboundtotheB29lysineaminoacid.InsulindetemirisslowlyabsorbedduetoitsstrongassociationwithalbumininthesubQtissueandwhenitreachesthebloodstreamitagainbindstoalbumindelayingitsdistributiontotheperipheraltissues.
Storage
Allinsulinshaveanexpirationdatewhichislabeledondirectlyontheproduct(vials,cartridges,disposablepensandotherdeliverydevices)applieswhentheyareunopenedandrefrigerated.Unopened(i.e.,insulinnotcurrentlyinuse)insulinshouldbestoredintherefrigeratorat36F46F(2C8C).Insulinshouldneverbefrozenorstoredinanambienttemperaturegreaterthan86F(30C).Aninsulinvialinusemaybekeptatroomtemperature,below86F,or30C(insulinglulisineandNovoNordiskhumaninsulins,N,Rand70/30,shouldbestoredupto77Fonly),for28days,orabout1month(exceptforinsulindetemirandNovoNordiskhumaninsulins,whichcanbekeptforupto42days).Insulincartridges,disposablepensandotherdeliverydevicescanhavedifferentstoragerecommendationsforroomtemperature.Onceopened,insulincartridgesandpensshouldnotberefrigerated.
AdverseEffects
Themostsignificantadverseeffectofinsulinishypoglycemia.IntheDCCT(DiabetesControlandComplicationsTrial),intensiveinsulintherapywasassociatedwitha23foldincreaseinseverehypoglycemia(i.e.,apersonrequiringassistance) .Likewise,intheUKPDS(UnitedKingdomProspectiveDiabetesStudy),insulintherapyintheintensivelytreatedgroupresultedin1.8%rateofmajorhypoglycemicepisodescomparedto0.7%intheconventionalgroup .Allpatientsreceivinginsulinshouldbeawareofthesymptomsofhypoglycemiaandhowtotreatit.
Weightgainisanothersignificantsideeffectofinsulintherapy.Inpart,theweightgaincanbearesultoffrequenthypoglycemicepisodesinwhichpatientsoftenovertreat/overeatinresponsetohunger.Insulin,beingananabolichormone,alsopromotestheuptakeoffattyacidsintoadiposetissue.TheamountofweightgainintheDCCTandUKPDSassociatedwithinsulintherapywas4.6kgand4.0kgrespectively .However,lessweightgainisencounteredwithlongactinginsulinanalogs .
Trueallergicreactionsandcutaneousreactionsarerare(seeImmunogenicity).Toavoidlipohypertrophy,patientsshouldbeinstructedtorotatetheirinsulininjectionsites,preferablyrotatingwithinonearea(e.g.,abdomenavoid2inchradiusaroundnavel)andnotreusingforoneweek .
InJune2009,4retrospective,epidemiologicstudiesassessingtheriskofcancerfrominsulinuse,glargineinparticular,werepublishedonlineattheEuropeanAssociationfortheStudyofDiabetes'journalwebsite3oftheseEuropeanstudiesreportedanincreasedriskofcancerwithinsulinglargine.IntheGermanystudy,acorrelationbetweeninsulindoseandcancerriskwasfoundforallinsulintypes(humaninsulin,aspart,lisproorglargine)howeverafteradjustingfordose,insulinglarginewasfoundtohaveadosedependentincreasedriskofcancercomparedtohumaninsulin(e.g.,HR1.09,1.19and1.31foratotaldailydosesof10units,30unitsand50unitsrespectively). Themedianfollowuptimewasonly1.63years(1.31yearsforinsulinglargine)andbodymassindexwasnotaccountedfor.TheSwedishstudyfoundastatisticallysignificantincreasedriskofbreastcanceronlyinwomenwhousedinsulinglarginealone(RR1.99),butnotinthoseoninsulinglargineplusotherinsulins. TheScotlandstudydemonstratedaincreasedriskofcancer(HR1.55)forpatientsoninsulinglarginealone,whilethoseoninsulinglargineplusotherinsulinshadaslightlylowerincidenceofcancer(HR0.81)comparedtohumaninsulinonlyuserswhichwasnotstatisticallysignificant.
[76] [77]
[78]
[79]
[80] [81]
[82] [83]
[84]
[85]
[86]
[87]
[88]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 12/24
Finally,intheUKstudy,nolinkbetweeninsulinglargineandcancerwasfound. Theseobservationalstudiesassessedlargepatientdatabasesandhavesignificant,inherentlimitationstogeneralizetheirconclusions,suchasthepotentialfordifferentpretreatmentcharacteristicsofthegroups,selectionbias,thesmallnumbersofcancercasesfound,andshortdurationoffollowup.Also,type2diabetesitselfisassociatedwithanincreasedriskofcolon,pancreasandbreastcancer.Furthermore,inarandomised,5year,openlabeltrialcomparingtheprogressionofretinopathyofNPHandinsulinglargineusers,noincreasedriskofcancerwasfoundinthe1017patientsample. Lastly,inananalysisof31randomizedcontrolledtrialsfromthesanofiaventissafetydatabase(phase2,3,and4studies),insulinglarginewasnotassociatedwithanincreasedriskofcancer,includingbreastcancer. Ofnote,themainstudyaffectingthesefindingsistheRosenstocketalstudycomparingglarginetoNPHthathadanapproximate5yearduration,whereas19ofthestudiesincludedhadveryshortdurations(approximately6months).OnJuly1,2009,theFDAissuedanearlycommunicationaboutthesafetyofLantusandisworkingwiththemanufacturertoreviewthecollectivedataanddeterminewhetheradditionalstudiesneedtobeperformed.Atthistime,thesedatadonotprovideconclusiveevidenceofanincreasedriskofcancerassociatedwithinsulinglargine.
TYPESOFREGIMENS
GeneralPrinciples
Type1Diabetes
Withdecreasingbetacellfunctionresultingindecreasedinsulinproduction,peoplewithtype1diabetesmayrequireinsulinforsurvival.Ingeneral,insulinopenictype1diabeticsgenerallyrequire0.51.0unitsperkgofbodyweightperdayofinsulin .Insulintherapyisofteninitiatedat0.50.75units/kg/day .Duringtheearlystagesoftype1diabetes,patientswillrequirelessinsulinbecausethebetacellsarestillproducingsomeinsulininsulinrequirementscanbeintherangeof0.10.6unitsperkgperday .Intensiveinsulintherapy(definedas3insulininjectionsdaily)isindicatedforpeoplewithtype1diabetesasthishasbeenshowntoprovidebetterglycemiccontrolthan1or2dailyinjectionsandreducethedevelopmentandprogressionofmicrovascularcomplications .
Type2Diabetes
Manypatientswithtype2diabeteswilleventuallyrequireinsulintherapy.Sincetype2diabetesisassociatedwithinsulinresistance,insulinrequirementscanexceed1unit/kg/day.IntheUKPDS,by9yearslessthan25%ofpatientstreatedwithasulfonylureaasmonotherapywereabletomaintainA1Clevels
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 13/24
Preprandialplasmaglucose70130mg/dl
Postprandialplasmaglucose
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 14/24
Figure5a.
Figure5b.
Figure5c.
TwicedailyInsulinRegimen(SplitMixedandPreMixedRegimens)
Twothirdsoftheinsulindoseisgiveninthemorningbeforebreakfastandonethirdisgivenbeforedinner.Premixedinsulinscanbeusedoramixtureofashortactinginsulin(e.g.,regular,insulinaspart/glulisine/lispro)andanintermediateactinginsulin(e.g.,NPH)(Figure6a) .[106]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 15/24
Figure6a.
2/3totaldailydoseatbreakfast:givenas2/3NPHand1/3Regular(orinsulinaspart/glulisine/lispro)
1/3totaldailydoseatdinner:dividedinequalamountsofNPHandRegular(orinsulinaspart/glulisine/lispro)
ForpatientswhoexperiencenocturnalhypoglycemiawhenNPHisadministeredatdinnerwithashortactinginsulin,movingtheNPHdosetobedtimehelpsreducetheriskfornocturnalhypoglycemia .Conversely,NPHatdinnercanresultinfastinghyperglycemiaduetodissipationofinsulinactivityandthedawnphenomenon.MovingtheNPHdosetobedtimecanhelpresolvethisproblem (Figure6b).Anobviouslimitationtousingpremixedinsulinisreducedflexibilityindosingifthedoseisadjusted,bothtypesofinsulininthemixtureareadjusted.
Figure6b.
MultipleDailyInsulinInjectionRegimen:BasalplusPrandialInsulin
Manydifferenttypesofregimensarepossiblewithmultipledailyinjections.Regular,insulinaspart,glulisineandlisproareusedtoprovideprandialinsulin.NPH,insulinglargine,andinsulindetemirareusedtoprovidebasalinsulin.
Regular,insulinaspart/glulisine/lisprobeforemealsandNPH,insulinglargineorinsulindetemiratbedtime(Figure7a,7b).
Insulinaspart/glulisine/lisprobeforemealsandNPHtwicedaily(breakfastandbedtime)(Figure8).
[107]
[108]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 16/24
Figure7a.
Figure7b.
Figure8.
InsulinPumps
Insulinpumporcontinuoussubcutaneousinsulininfusion(CSII)therapyisanotheroptionforintensiveinsulintherapy.Whilepumptherapyusedtobereservedforprimarilytype1diabetes,patientswithtype2diabetesarenowusinginsulinpumps .Patientsinitiatedoninsulinpumptherapyneedtobeveryknowledgeableaboutdiabetesmanagementandbepracticingselfmanagement.Patientsalreadyknowhowtocountcarbohydratesandadjusttheir
[109]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 17/24
insulindoses.Potentialadvantagesofinsulinpumpsincludelessweightgain,lesshypoglycemia,andbettercontroloffastinghyperglycemiaduetothedawnphenomenoncomparedtomultipledailyinjections .
TimingofPrandialInsulinInjection
Thelagtimefrominjectingregularinsulinandeatingisapproximately30minuteswhileinsulinaspart/glulisine/lisprocanbeinjectedwithin15minutesofeating.Dependingonthelevelofhyperglycemiabeforemeals,thelagtimecanbeincreased.Rapidactinginsulinsallowpatientstoadjustinsulintomatchtheirlifestyleratherthanhavingtoadaptthetimingofmealstoamorefixedinsulinregimen .
Adjustments
Insulindosesshouldbeadjustedtoachieveglycemictargets.Itisalwaysbesttoerrontheconservativesidewhendosinginsulinatinitiationorwhenadjustingcurrentinsulintherapy.Typicallya1020%increaseordecreaseinaninsulindoseisappropriate.Ifapatientisexperiencinghypoglycemia,adjustmentoftheinsulindosecausingthehypoglycemiashouldbeaddressedpreferentiallyoverotherinsulindoseadjustments.Hyperglycemiaisadominoeffect:ifapatientishyperglycemicinthemorning,chancesaretheyremainhyperglycemicthroughouttheday.Therefore,adjusttheearliesttimeofhyperglycemiafirst .
AdjustmentofIntermediatetoLongActingInsulin
Whenadoseofintermediateorlongactinginsulinisadjusted,itisrecommendedtowaitatleast25daysbeforefurtherchangesinthedosetoassesstheresponse .
AdjustmentofOnceDailyEveningInsulin
TheFPGisusedtoadjusttheintermediatetolongactinginsulingivenintheevening.Acommonweeklytitrationscheduleusedis :
IftheFPGis>140mg/dl:Increaseby4units
IftheFPGis120140mg/dl:Increaseby2units
Forinsulinglargine,thefollowingtitrationschedulehasbeenstudiedandshowntocauselessnocturnalhypoglycemiacomparedtobedtimeNPHinsulin.Inthisstudy,insulinwastitrated,usingaforcedtitrationschedule,totargetaFPGof100mg/dl .
ForcedTitrationScheduleStartwith10unitsbedtimebasalinsulindoseadjustweekly
FPG(mg/dL) Increaseinsulindose
100120 2
120140 4
140180 6
180 8
Decreaseinsulindose(e.g.,24units/day)ifhypoglycemiaoccurs.(modifiedrecommendationfromreference112)
SupplementalInsulinforCorrectionofHyperglycemia
Regularinsulin,insulinaspart/glulisine/lisprocanbeusedtocorrectforhyperglycemia .Ingeneral,12unitsofinsulinwilllowerthebloodglucoseby3050mg/dl.Often1unitforevery50mg/dlabovetheglucosetargetisastartingsupplementaldose,adjustingforinsulinsensitivity .Anexampleofasupplementalinsulinregimenisasfollows:Forevery50mg/dlabovethepremealglucosetarget(e.g.,150mg/dl),add1unitofinsulin .So,ifa
[110] [111] [112] [113]
[114]
[115]
[116]
[117]
[118]
[119]
[120]
[121]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 18/24
1.
2.
3.
4.
personspremealglucosewas250mg/dl,2unitsofinsulinwouldbeaddedtotheusualdoseofpremealinsulin.Supplementalinsulincanalsobeusedforsnacks .
CarbohydrateCounting
Amoresophisticatedtypeofinsulinregimenisoneinwhichapatientdosestheirprandialinsulinbasedonthenumberofcarbohydrateseatenatthemeal.Bylearninghowtocounttheircarbohydrates,anddosingtheirinsulinaccordingly,patientsareaffordedflexibilityintheirmeals.Astartinginsulintocarbohydraterationoftenusedis1unitofinsulinforevery15gramsofcarbohydrate .Thisratioisadjustedbasedoninsulinsensitivityandmaybedifferentforeachmeal.Carbohydratecountingistoodifficultforsomepatients.Inthesepatients,mealportionsizesandestimatesofcarbohydrateservings(15grams)areconceptsthatcanbelearned.Medicalnutritiontherapyisacriticalcomponentoftherapyforpatientsoninsulin.
Acomprehensivediabeteseducationclass,thatteachesselfmanagementskills,suchashowtodoseprandialinsulinbymatchingittotheamountofcarbohydrateintakeareanexcellentresourcetofacilitatepatientsinadoptinganintensiveinsulintherapyregimen .
AdjustmentsforExercise
Exerciseimprovesinsulinsensitivity.Thus,whenapatientexercises,itisoftennecessarytodecreasetheinsulindose(andincreasecaloricintake).Formorningexercise,theprebreakfastinsulindoseshouldbereduced(~25%dependingonthedurationandintensityoftheexercise).Forlatemorning/earlyafternoonandeveningexercise,theprelunchandpredinnerinsulindoseshouldbereducedrespectively .Theeffectofexerciseoninsulinsensitivitycanlastformanyhourssoseveralinsulindosesmayneedtobeadjusted.
SelfMonitoringofBloodGlucose
Patientswhowerenotselfmonitoringtheirbloodglucose(SMBG)levelspriortoinsulinneedtobeeducatedhowtodothis,howtointerprettheirglucosereadings,andhowtotreathypoglycemiaifitoccurs.Involvementofdiabeteseducatorisextremelyusefulwheninitiatingpatientsoninsulintoprovidecomprehensiveselfmanagementtraining.TheADAcurrentlyrecommendthatpeoplewithtype1diabetesSMBGatleast3timesdailyandthosewithtype2diabetesatleastdaily .Mostglucosemetersarenowplasmareferenced,correlatingbettertotheADAsglycemicgoals.Plasmaglucoseconcentrationsareapproximately1015%higherthanwholebloodglucoseconcentrations .
SICKDAYGUIDELINES
Acommonmisconceptionamongpatientsisthatiftheyaresickenoughthattheydonteatorevenvomit,theyshouldnottaketheirdiabetesmedications,insulinincluded.Patientsshouldbeinstructedtocontinuetheirinsulintherapy,maintainfluidintake,eatsmallermealsastolerated,andtesttheirglucoselevelsevery14hours(ketonesaswellforpeoplewithtype1diabetes).Insulintherapyshouldbeadjustedbasedontheglucoselevels.Iftheglucoseis>240mg/dlwithmoderatetolargeketonuria,patientsshouldcontacttheirproviderimmediately .
References
BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.FDA/CDERresourcespage.Frequentlyaskedquestionsaboutimportingbeeforporkinsulinforpersonaluse.FoodandDrugAdministrationwebsite.Availableat:http://www.fda.gov/cder/drug/beefandporkinsulin/default.htm.AccessedSeptember16,2006.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.May2004EliLillyandCompany.HumalogPackageInsert.
[122]
[123]
[124]
[125]
[126]
[127]
[128]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 19/24
5.6.7.8.9.10.11.12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.23.
24.
25.
26.
27.
28.29.30.31.
32.33.
34.
March2005EliLillyandCompany.HumalogMix75/25PackageInsert.February2006SanofiAventisU.S.LantusPackageInsert.October2005NovoNordisk,Inc.NovologPackageInsert.November2005NovoNordiskInc.NovologMix70/30PackageInsert.January2006EliLillyandCompany.HumalogMix50/50PackageInsert.October2005NovoNordiskInc.LevemirPackageInsert.November2005AventisPharmaceuticalsInc.ApidraPackageInsert.KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenicpotenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenicpotenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]HomePD,AshwellSG2002Anoverviewofinsulinglargine.DiabetesMetabResRev18Suppl3:S5763.[PubMed:12324987]SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16Suppl3:15565.[PubMed:8299472]SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16Suppl3:15565.[PubMed:8299472]BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16Suppl3:15565.[PubMed:8299472]SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16Suppl3:15565.[PubMed:8299472]SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16Suppl3:15565.[PubMed:8299472]March2007sanofiaventisU.S.LCC.LantusPackageInsert.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.KroonLA,AssemiM,CarlisleBA.2009DiabetesMellitus.In:AppliedTherapeutics:TheClinicalUseofDrugs,9thedition.KodaKimbleMA,YoungLY,AlldredgeBA,CorelliRL,GuglielmoBJ,KradjanWA,WilliamsBR,eds.Lippincott,Williams&Wilkins:Baltimore,MD.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.March2009EliLillyandCompany.HumalogPackageInsert.March2008NovoNordisk,Inc.NovologPackageInsert.February2009sanofiaventisU.S.LCC.ApidraPackageInsert.terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsandglucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]March2007sanofiaventisU.S.LCC.LantusPackageInsert.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenic
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 20/24
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.46.47.48.49.50.51.
52.
53.
54.
55.
56.
57.
58.
59.
potenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]HomePD,AshwellSG2002Anoverviewofinsulinglargine.DiabetesMetabResRev18Suppl3:S5763.[PubMed:12324987]BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.FrancisAJ,HanningI,AlbertiKG1985Theinfluenceofinsulinantibodylevelsontheplasmaprofilesandactionofsubcutaneouslyinjectedhumanandbovineshortactinginsulins.Diabetologia28:3304.[PubMed:3899818]terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsandglucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]NolteMS,Karam,J.H.2001PancreaticHormones&AntidiabeticDrugs.In:KatzungB(ed)BasicandClinicalPharmacology,8thed.LangeMedicalBooks/McGrawHill,NewYork,pp711734.RabkinR,RyanMP,DuckworthWC1984Therenalmetabolismofinsulin.Diabetologia27:3517.[PubMed:6389240]RoachP,WoodworthJR2002Clinicalpharmacokineticsandpharmacodynamicsofinsulinlispromixtures.ClinPharmacokinet41:104357.[PubMed:12403642]RaveK,etal.2005Timeactionprofileofinhaledinsulinincomparisonwithsubcutaneouslyinjectedinsulinlisproandregularhumaninsulin.DiabetesCare2810771082.[PubMed:15855570]PlankJ,etal.2005.Adoubleblind,randomized,doseresponsestudyinvestigatingthepharmacodynamicandpharmacokineticpropertiesofthelongactinginsulinanalogdetemir.DiabetesCare2811071112.[PubMed:15855574]LeporeM,etal.2000.Pharmacokineticsandpharmacodynamicsofsubcutaneousinjectionoflongactinghumaninsulinanalogglargine,NPHinsulin,andultralentehumaninsulinandcontinuoussubcutaneousinfusionofinsulinlispro.Diabetes4921422148.[PubMed:11118018]March2009EliLillyandCompany.HumalogPackageInsert.March2009EliLillyandCompany.HumalogMix75/25PackageInsert.March2007sanofiaventisU.S.LCC.LantusPackageInsert.March2008NovoNordisk,Inc.NovologPackageInsert.October2007NovoNordiskInc.NovologMix70/30PackageInsert.May2007NovoNordiskInc.LevemirPackageInsert.KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenicpotenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]HomePD,AshwellSG2002Anoverviewofinsulinglargine.DiabetesMetabResRev18Suppl3:S5763.[PubMed:12324987]KroonLA,AssemiM,CarlisleBA.2009DiabetesMellitus.In:AppliedTherapeutics:TheClinicalUseofDrugs,9thedition.KodaKimbleMA,YoungLY,AlldredgeBA,CorelliRL,GuglielmoBJ,KradjanWA,WilliamsBR,eds.Lippincott,Williams&Wilkins:Baltimore,MD,pp5017.terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsandglucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]FrancisAJ,HanningI,AlbertiKG1985Theinfluenceofinsulinantibodylevelsontheplasmaprofilesandactionofsubcutaneouslyinjectedhumanandbovineshortactinginsulins.Diabetologia28:3304.[PubMed:3899818]NolteMS,Karam,J.H.2001PancreaticHormones&AntidiabeticDrugs.In:KatzungB(ed)BasicandClinicalPharmacology,8thed.LangeMedicalBooks/McGrawHill,NewYork,pp711734.RabkinR,RyanMP,DuckworthWC1984Therenalmetabolismofinsulin.Diabetologia27:3517.[PubMed:6389240]BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.PampanelliS,TorloneE,IalliC,etal.1995ImprovedpostprandialmetaboliccontrolaftersubcutaneousinjectionofashortactinginsulinanaloginIDDMofshortdurationwithresidualpancreaticbetacellfunction.Diabetes
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 21/24
60.
61.
62.
63.
64.
65.
66.
67.
68.69.
70.
71.72.73.74.
75.
76.
77.
78.
79.
Care18:14529.[PubMed:8722069]BrunelleBL,LlewelynJ,AndersonJH,Jr.,GaleEA,KoivistoVA1998Metaanalysisoftheeffectofinsulinlisproonseverehypoglycemiainpatientswithtype1diabetes.DiabetesCare21:172631.[PubMed:9773738]LalliC,CiofettaM,DelSindacoP,etal.1999Longtermintensivetreatmentoftype1diabeteswiththeshortactinginsulinanaloglisproinvariablecombinationwithNPHinsulinatmealtime.DiabetesCare22:46877.[PubMed:10097931]LalliC,CiofettaM,DelSindacoP,etal.1999Longtermintensivetreatmentoftype1diabeteswiththeshortactinginsulinanaloglisproinvariablecombinationwithNPHinsulinatmealtime.DiabetesCare22:46877.[PubMed:10097931]ZinmanB,TildesleyH,ChiassonJL,TsuiE,StrackT1997InsulinlisproinCSII:resultsofadoubleblindcrossoverstudy.Diabetes46:4403.[PubMed:9032100]KaufmanFR,HalvorsonM,KimC,PitukcheewanontP2000Useofinsulinpumptherapyatnighttimeonlyforchildren710yearsofagewithtype1diabetes.DiabetesCare23:57982.[PubMed:10834412]RennerR,PfutznerA,TrautmannM,HarzerO,SauterK,LandgrafR1999Useofinsulinlisproincontinuoussubcutaneousinsulininfusiontreatment.Resultsofamulticentertrial.GermanHumalogCSIIStudyGroup.DiabetesCare22:7848.[PubMed:10332682]KumarD1997Lisproanalogfortreatmentofgeneralizedallergytohumaninsulin.DiabetesCare20:13579.[PubMed:9283778]RaskinP,GuthrieRA,LeiterL,RiisA,JovanovicL2000Useofinsulinaspart,afastactinginsulinanalog,asthemealtimeinsulininthemanagementofpatientswithtype1diabetes.DiabetesCare23:5838.[PubMed:10834413]March2008NovoNordisk,Inc.NovologPackageInsert.BodeBW,StrangeP2001Efficacy,safety,andpumpcompatibilityofinsulinaspartusedincontinuoussubcutaneousinsulininfusiontherapyinpatientswithtype1diabetes.DiabetesCare24:6972.[PubMed:11194244]terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsandglucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]February2009sanofiaventisU.S.LCC.ApidraPackageInsert.BolliGB,OwensDR2000Insulinglargine.Lancet356:4435.[PubMed:10981882]BolliGB,OwensDR2000Insulinglargine.Lancet356:4435.[PubMed:10981882]HeinemannL,LinkeschovaR,RaveK,HompeschB,SedlakM,HeiseT2000Timeactionprofileofthelongactinginsulinanaloginsulinglargine(HOE901)incomparisonwiththoseofNPHinsulinandplacebo.DiabetesCare23:6449.[PubMed:10834424]MudaliarS,MohideenP,DeutschR,etal.2002.Intravenousglargineandregularinsulinhavesimilareffectsonendogenousglucoseoutputandperipheralactivation/deactivationkineticprofiles.DiabetesCare25:1597602.[PubMed:12196433]YkiJarvinenH,DresslerA,ZiemenM.2000.LessnocturnalhypoglycemiaandbetterpostdinnerglucosecontrolwithbedtimeinsulinglarginecomparedwithbedtimeNPHinsulinduringinsulincombinationtherapyintype2diabetes.HOE901/3002StudyGroup.DiabetesCare23:11306.[PubMed:10937510]RatnerRE,HirschIB,NeifingJL,GargSK,MeccaTE,WilsonCA2000Lesshypoglycemiawithinsulinglargineinintensiveinsulintherapyfortype1diabetes.U.S.StudyGroupofInsulinGlargineinType1Diabetes.DiabetesCare23:63943.[PubMed:10834423]TheDiabetesControlandComplicationsTrialResearchGroup.1993.Theeffectofintensivetreatmentofdiabetesonthedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.NEnglJMed329:97786.[PubMed:8366922]UKProspectiveDiabetesStudy(UKPDS)Group.1998.Intensivebloodglucosecontrolwithsulphonylureasorinsulincomparedwithconventionaltreatmentandriskofcomplicationsinpatientswithtype2diabetes(UKPDS33).Lancet352:83753.[PubMed:9742976]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 22/24
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.95.
96.
97.
TheDiabetesControlandComplicationsTrialResearchGroup.1993.Theeffectofintensivetreatmentofdiabetesonthedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.NEnglJMed329:97786.[PubMed:8366922]
UKProspectiveDiabetesStudy(UKPDS)Group.1998.Intensivebloodglucosecontrolwithsulphonylureasorinsulincomparedwithconventionaltreatmentandriskofcomplicationsinpatientswithtype2diabetes(UKPDS33).Lancet352:83753.[PubMed:9742976]MeneghiniLF,RosenbergKH,KoenenC,MerilainenMJ,LddekeHJ.2007.Insulindetemirimprovesglycaemiccontrolwithlesshypoglycaemiaandnoweightgaininpatientswithtype2diabeteswhowereinsulinnaiveortreatedwithNPHorinsulinglargine:clinicalpracticeexperiencefromaGermansubgroupofthePREDICTIVEstudy*Diabetes,ObesityandMetabolism9(3)418427.[PubMed:17391170]RosenstockJ,DaviesM,HomePD,LarsenJ,KoenenC,SchernthanerG.2008.Arandomised,52week,treattotargettrialcomparinginsulindetemirwithinsulinglarginewhenadministeredasaddontoglucoseloweringdrugsininsulinnaivepeoplewithtype2diabetes.Diabetologia51(3):408416.[PMCfreearticle:PMC2235909][PubMed:18204830]ADA.2004.AmericanDiabetesAssociationPositionStatement.Insulinadministration.DiabetesCare27Suppl1:S106109.[PubMed:14693942]HemkinsLG,GrouvenU,BenderRetal.2009.Riskofmalignanciesinpatientswithdiabetestreatedwithhumaninsulinorinsulinsanalogues:acohortstudy.Diabetologia52:17321744.[PMCfreearticle:PMC2723679][PubMed:19565214]JonassonJM,LjungR,TlbackMetal.2009.InsulinglargineuseandshorttermincidenceofmalignanciesapopulationbasedfollowupstudyinSweden.Diabetologia52:17451754.[PubMed:19588120]ColhounHM,onbehalfoftheSDRNEpidemiologyGroup.2009.UseofinsulinglargineandcancerincidenceinScotland:astudyfromtheScottishDiabetesResearchNetworkEpidemiologyGroup.Diabetologia52:17551765.[PMCfreearticle:PMC2723678][PubMed:19603149]CurrieCJ,PooleCD,2009.GaleEAMTheinfluenceofglucoseloweringtherapiesoncancerriskintype2diabetes.Diabetologia52:17661777.[PubMed:19572116]RosenstockJ,FonsecaV,McGillJBetal.2009.SimilarriskofmalignancywithinsulinglargineandneutralprotamineHagedorn(NPH)insulininpatientswithtype2diabetes:findingsfroma5yearrandomized,openlabelstudy.Diabetologia52:17781788.[PMCfreearticle:PMC2723677][PubMed:19609501]HomePD,LagarenneP.2009.Combinedrandomisedcontrolledtiralexperienceofmalignanciesinstudiesusinginsulinglargine.Diabetologiadoi:10.1007/s0012500915305.[PMCfreearticle:PMC2776153][PubMed:19756478]HirschIB1999Type1diabetesmellitusandtheuseofflexibleinsulinregimens.AmFamPhysician60:234352,23556.[PubMed:10593324]HirschIB1999Type1diabetesmellitusandtheuseofflexibleinsulinregimens.AmFamPhysician60:234352,23556.[PubMed:10593324]ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.2002Practicalinsulin:Ahandbookforprescribingproviders.AmericanDiabetesAssociation,Alexandria,VA.1993TheDiabetesControlandComplicationsTrialResearchGroup.Theeffectofintensivetreatmentofdiabetesonthedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.NEnglJMed329:97786.[PubMed:8366922]TurnerRC,CullCA,FrighiV,HolmanRR1999Glycemiccontrolwithdiet,sulfonylurea,metformin,orinsulininpatientswithtype2diabetesmellitus:progressiverequirementformultipletherapies(UKPDS49).UKProspectiveDiabetesStudy(UKPDS)Group.Jama281:200512.[PubMed:10359389]HermannLS2000Optimisingtherapyforinsulintreatedtype2diabetesmellitus.DrugsAging17:28394.[PubMed:11087006]
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 23/24
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.115.
116.
117.
118.
119.
HermannLS2000Optimisingtherapyforinsulintreatedtype2diabetesmellitus.DrugsAging17:28394.[PubMed:11087006]
DeWittDE,DugdaleDC2003Usingnewinsulinstrategiesintheoutpatienttreatmentofdiabetes:clinicalapplications.Jama289:22659.[PubMed:12734138]YkiJarvinenH2001Combinationtherapieswithinsulinintype2diabetes.DiabetesCare24:75867.[PubMed:11315844]ADA2009Standardsofmedicalcareindiabetes2009.DiabetesCare32Suppl1:S1361.[PMCfreearticle:PMC2613589][PubMed:19118286]1993TheDiabetesControlandComplicationsTrialResearchGroup.Theeffectofintensivetreatmentofdiabetesonthedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.NEnglJMed329:97786.[PubMed:8366922]RoachP,WoodworthJR2002Clinicalpharmacokineticsandpharmacodynamicsofinsulinlispromixtures.ClinPharmacokinet41:104357.[PubMed:12403642]ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.FanelliCG,PampanelliS,PorcellatiF,RossettiP,BrunettiP,BolliGB2002AdministrationofneutralprotamineHagedorninsulinatbedtimeversuswithdinnerintype1diabetesmellitustoavoidnocturnalhypoglycemiaandimprovecontrol.Arandomized,controlledtrial.AnnInternMed136:50414.[PubMed:11926785]FrancisAJ,HomePD,HanningI,AlbertiKG,TunbridgeWM1983Intermediateactinginsulingivenatbedtime:effectonbloodglucoseconcentrationsbeforeandafterbreakfast.BrMedJ(ClinResEd)286:11736.[PMCfreearticle:PMC1547399][PubMed:6404377]RaskinP,BodeBW,MarksJB,etal.2003Continuoussubcutaneousinsulininfusionandmultipledailyinjectiontherapyareequallyeffectiveintype2diabetes:arandomized,parallelgroup,24weekstudy.DiabetesCare26:2598603.[PubMed:12941725]MudaliarS,EdelmanSV2001Insulintherapyintype2diabetes.EndocrinolMetabClinNorthAm30:93582.[PubMed:11727406]BodeBW,SabbahHT,GrossTM,FredricksonLP,DavidsonPC2002Diabetesmanagementinthenewmillenniumusinginsulinpumptherapy.DiabetesMetabResRev18Suppl1:S1420.[PubMed:11921425]BodeBW,TamborlaneWV,DavidsonPC2002Insulinpumptherapyinthe21stcentury.Strategiesforsuccessfuluseinadults,adolescents,andchildrenwithdiabetes.PostgradMed111:6977quiz27.[PubMed:12040864]PickupJ,KeenH2002Continuoussubcutaneousinsulininfusionat25years:evidencebasefortheexpandinguseofinsulinpumptherapyintype1diabetes.DiabetesCare25:5938.[PubMed:11874953]February2009.sanofiaventisU.S.LCC.ApidraPackageInsert.ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.MudaliarS,EdelmanSV2001Insulintherapyintype2diabetes.EndocrinolMetabClinNorthAm30:93582.[PubMed:11727406]RiddleMC,RosenstockJ,GerichJ2003Thetreattotargettrial:randomizedadditionofglargineorhumanNPHinsulintooraltherapyoftype2diabeticpatients.DiabetesCare26:30806.[PubMed:14578243]HollemanF,vandenBrandJJ,HovenRA,etal.1996ComparisonofLysB28,ProB29humaninsulinanalog
-
25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf
http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 24/24
120.
121.
122.
123.
124.
125.
126.
127.
128.
andregularhumaninsulininthecorrectionofincidentalhyperglycemia.DiabetesCare19:14269.[PubMed:8941477]MudaliarS,EdelmanSV2001Insulintherapyintype2diabetes.EndocrinolMetabClinNorthAm30:93582.[PubMed:11727406]DeWittDE,HirschIB2003Outpatientinsulintherapyintype1andtype2diabetesmellitus:scientificreview.Jama289:225464.[PubMed:12734137]KongN,KitchenMM,RyderRE2000Theuseoflisproforhighsugarcontentsnacksbetweenmealsinintensiveinsulinregimens.DiabetMed17:3312.[PubMed:10821304]HirschIB1999Type1diabetesmellitusandtheuseofflexibleinsulinregimens.AmFamPhysician60:234352,23556.[PubMed:10593324]2002Traininginflexible,intensiveinsulinmanagementtoenabledietaryfreedominpeoplewithtype1diabetes:doseadjustmentfornormaleating(DAFNE)randomisedcontrolledtrial.Bmj325:746.[PMCfreearticle:PMC128375][PubMed:12364302]ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.ADA2009Standardsofmedicalcareindiabetes2009.DiabetesCare32Suppl1:S1361.[PMCfreearticle:PMC2613589][PubMed:19118286]StahlM,BrandslundI,JorgensenLG,HyltoftPetersenP,BorchJohnsenK,deFineOlivariusN2002Cancapillarywholebloodglucoseandvenousplasmaglucosemeasurementsbeusedinterchangeablyindiagnosisofdiabetesmellitus?ScandJClinLabInvest62:15966.[PubMed:12004932]ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.
Copyright20002015,MDText.com,Inc.
ThiselectronicversionhasbeenmadefreelyavailableunderaCreativeCommons(CCBYNCND)license.Acopyofthelicensecanbeviewedathttp://creativecommons.org/licenses/byncnd/2.0/.
BookshelfID:NBK278938 PMID:25905175